Navigation Links
Ceregene And Alzheimer's Disease Cooperative Study Group Complete Enrollment Of CERE-110 Phase 2 Trial
Date:3/13/2013

SAN DIEGO, March 13, 2013 /PRNewswire/ -- Ceregene, Inc. today announced the completion of enrollment in its double-blind Phase 2 clinical study of CERE-110 (AAV-NGF), a gene therapy product designed to deliver nerve growth factor (NGF) for the treatment of Alzheimer's disease. The clinical study was carried out in collaboration with the Alzheimer's Disease Cooperative Study (ADCS) based at the University of California San Diego (UCSD) and funded by a grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH).  

Forty-nine (49) patients with mild to moderate Alzheimer's disease were treated with CERE-110 at 10 clinical sites throughout the U.S. Approximately half of the patients received CERE-110 while the other half received an appropriate sham (placebo) surgery control treatment. Patients will be followed for a minimum of two years with respect to safety, brain imaging, as well as measures of cognitive function and quality of life. Standard tests used in Alzheimer's clinical trials.

"We are very excited that enrollment in the first blinded study of NGF gene therapy for Alzheimer's disease is now completed and appreciate the courage of all of the patients and their family members that enrolled in this very important study. We also appreciate the efforts of the ADCS and the National Institute on Aging for carrying out and supporting the operational aspects of this study" stated Jeffrey M. Ostrove , Ph.D., president and chief executive officer of Ceregene, Inc., the developer of CERE-110. Dr. Ostrove added "In addition to CERE-110 for Alzheimer's disease, we have also completed enrollment in two controlled Phase 2 clinical trials of CERE-120 for Parkinson's disease. At this time, we would like to recognize the leadership role of Raymond T. Bartus , Ph.D., our chief scientific officer who led the development effor
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
2. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
3. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
4. Alzheimers Drug Discovery Foundation Awards Grant To CohBar to Develop A Novel Peptide Therapeutic For Alzheimers Disease
5. Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential
6. Parkinsons Disease: World Drug Market 2013-2023
7. NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinsons Disease
8. Adventrx To Develop ANX-188 For Complications Of Arterial Disease
9. Aethlon Medical (AEMD) Note: Multiple Shots on Goal - A Therapeutic Strategy to Address Infectious Disease & Cancer
10. Independent Study Published in Clinical Infectious Diseases Highlights the Importance of Antimicrobial Removal Systems in Blood Culture to Rapidly and Accurately Aid in the Diagnosis of Sepsis
11. Shire Supports Rare Disease Day 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, today announced validation by ... Authorization Application (MAA) for sebelipase alfa for LAL ... for accelerated assessment, which has the potential to ... The MAA, and the Biologics License Application ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Neuro Kinetics, Inc. (NKI) ( www.neuro-kinetics.com ), manufacturers of ... vestibular and neurological conditions, said today that it co-presented ... conference meeting in Scottsdale, Arizona. The research ... clinical testing that can be conducted with its medical ...
... 2011 IRIDEX Corporation (Nasdaq: IRIX ) today reported ... improved financial results for the fourth quarter ended January 1, 2011. ... per share, up from $0.5 million or $0.05 per diluted share ... to $12.2 million in the 2010 fourth quarter, up 6% from ...
Cached Medicine Technology:Neuro Kinetics Presenting New Balance & Dizziness Research at American Balance Society Conference 2IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter 2IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter 3IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter 4IRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter 5
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online ... its collection of discounted prom dresses, most of which ... spokesman of the company, the promotion is valid until ... to expand the UK market. , The prom dresses ... lengths, and styles: A-line strapless, empire strapless chiffon, one ...
(Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
(Date:12/25/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Among early ... treatment, less than half of one percent will eventually ... new analysis reveals. The finding comes from a ... between 1998 and 2007, and it suggests that the ... double what experts had previously thought. "The frequency ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios have ... business presentation tool made specifically for Final Cut ... tool, users can now display their stats and facts ... Studios. “ProFire 5k gives users a multiple options to ... a presentation” , Pixel Film Studios takes the heat ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... BD (Becton, Dickinson and Company) (NYSE: BDX ), a global medical technology company, ... , Bank of America and Merrill Lynch 2009 ... 8:40 a.m. EDT, Bernstein,s ... 2009, 9:00 a.m. EDT, ...
... (Nasdaq: WCRX ) announced today that one ... ("Mayne") have filed a second lawsuit against Mylan Pharmaceuticals ... for the District of New Jersey for infringement of ... covers DORYX, a tetracycline-class oral antibiotic. The lawsuit ...
... better understood after taking hands-on approach , , FRIDAY, May ... specific training and tools can help young doctors do ... patients. , Seniors face added challenges with prescriptions, ... one time. Avoiding their greater susceptibility to side effects ...
... Award Honoring the Work of Oncology , NursesSAN ANTONIO, ... CURE magazine,s 2009 Extraordinary Healer Award for Oncology ... during a special reception at the Oncology Nursing Society,s ... patients and caregivers submitted nominations. The winner, Christine ...
... continues; Obama urges calm; global cases total 331 in 11 ... -- The number of confirmed swine flu cases in the ... health officials reported on Friday. , "That,s up eight states ... the U.S. Centers for Disease Control and Prevention,s science ...
... May 1 As the world sits on the ... attempting to reduce the ranks of personnel most skilled ... representing more than 20,000 Registered Nurses in 89 bargaining ... hospitals to reopen contracts regarding wages. In the ...
Cached Medicine News:Health News:Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent 2Health News:Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent 3Health News:Prescription Training Puts Docs in Shoes of Older Patients 2Health News:Winner of 2009 CURE Magazine Extraordinary Healer Award Announced 2Health News:Winner of 2009 CURE Magazine Extraordinary Healer Award Announced 3Health News:Swine Flu Infections Now at 141 in 19 U.S. States 2Health News:Swine Flu Infections Now at 141 in 19 U.S. States 3Health News:Swine Flu Infections Now at 141 in 19 U.S. States 4Health News:Swine Flu Infections Now at 141 in 19 U.S. States 5Health News:Swine Flu Infections Now at 141 in 19 U.S. States 6Health News:Swine Flu Infections Now at 141 in 19 U.S. States 7Health News:Swine Flu Infections Now at 141 in 19 U.S. States 8Health News:Swine Flu Infections Now at 141 in 19 U.S. States 9Health News:Hospital Staffing Cuts - Pragmatic, Panic or Carefully Planned? 2Health News:Hospital Staffing Cuts - Pragmatic, Panic or Carefully Planned? 3